👀 Copy Legendary Investors' Portfolios in One ClickCopy For Free

J&J shares on track for biggest daily drop in 3 years on talc setback

Published 07/31/2023, 03:30 PM
Updated 07/31/2023, 03:41 PM
© Reuters. A bottle of Johnson and Johnson Baby Powder is seen in a photo illustration taken in New York, February 24, 2016. REUTERS/Shannon Stapleton/Illustration
MS
-
JNJ
-

(Reuters) - Shares in Johnson & Johnson (NYSE:JNJ) were down 4.1% on Monday and looked set for their biggest one-day percentage loss since June 2020 after a U.S. judge shot down its second attempt to resolve tens of thousands of talc-related lawsuits.

Johnson & Johnson has now failed twice to resolve talc suits by offloading the related liabilities into a new company and placing it into bankruptcy. Lawsuits had alleged baby powder and other talc products sometimes contained asbestos and caused mesothelioma, ovarian cancer and other cancers.

J&J has said its talc products are safe and do not contain asbestos. The company said it would appeal Friday's dismissal, which imperils a proposed $8.9 billion settlement aimed at stopping new lawsuits.

In January a U.S. appeals court had also shot down J&J's earlier attempt to offload lawsuits via bankruptcy, in the first major repudiation of an emerging legal strategy with the potential to upend U.S. corporate liability law.

"In our view the talc litigation remains an overhang on the stock," wrote Morgan Stanley (NYSE:MS) analyst Terence Flynn in a research note after Friday's ruling.

The stock last traded at $167.33 after hitting its lowest level since July 20.

© Reuters. A bottle of Johnson and Johnson Baby Powder is seen in a photo illustration taken in New York, February 24, 2016. REUTERS/Shannon Stapleton/Illustration

Flynn, who rates J&J stock 'equal-weight,' has a $187 price target on the stock compared with the median Wall Street price target of $180, according to Refinitiv which shows 23 analysts covering J&J.

In August 2022 J&J said it would stop selling talc-based baby powder globally in 2023, more than two years after it ended U.S. sales of the product.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.